ReviewBritish journal of clinical pharmacology2013
Stratified approaches to the treatment of asthma.
Review in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- An update and systematic review on drug therapies for the treatment of refractory chronic cough.Expert opinion on pharmacotherapy · 2018Pooled it
- Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma.Canadian respiratory journalTrial
- Evaluating the Influence ofBiomolecules · 2025Article
- Editorial: Impact of system biology and molecular medicine on the management of complex immune mediated respiratory diseases, volume II.Frontiers in medicine · 2023Article
- A systems immunology approach identifies the collective impact of 5 miRs in Th2 inflammation.JCI insight · 2018Article
- Nonallergic Asthma and Its Severity: Biomarkers for Its Discrimination in Peripheral Samples.Frontiers in immunology · 2018Article
- Broad perspectives of allergen specific immunotherapy.Human vaccines & immunotherapeutics · 2017Article
- Inhaled protein/peptide-based therapies for respiratory disease.Molecular and cellular pediatrics · 2016Review
- Treatment response according to small airway phenotypes: a real-life observational study.Therapeutic advances in respiratory disease · 2016Observational
- A Novel Application of Ti-Substituted Polyoxometalates: Anti-Inflammatory Activity in OVA-Induced Asthma Murine Model.Bioinorganic chemistry and applications · 2016Article
- Future Research Directions in Asthma. An NHLBI Working Group Report.American journal of respiratory and critical care medicine · 2015Review
- Asthma.Nature reviews. Disease primers · 2015Review
- NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.Antioxidants & redox signaling · 2015Review
- Why aren't we doing better in asthma: time for personalised medicine?NPJ primary care respiratory medicine · 2015Review
- Microbiome and Asthma: What Have Experimental Models Already Taught Us?Journal of immunology research · 2015Review
- Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA - an observational, 2 phase, patient reported outcomes study.Clinical and molecular allergy : CMA · 2015Article
- Mast cells in human airways: the culprit?European respiratory review : an official journal of the European Respiratory Society · 2014Review
- Aligning mouse models of asthma to human endotypes of disease.Respirology (Carlton, Vic.) · 2014Review
- Asthma genetics and personalised medicine.The Lancet. Respiratory medicine · 2014Review
- Biomarkers for combat-related PTSD: focus on molecular networks from high-dimensional data.European journal of psychotraumatology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
While asthma is a chronic inflammatory disorder that is managed with inhaled controller and reliever drugs, there remains a large unmet need at the severe end of the disease spectrum. Here, a novel stratified approach to its treatment is reviewed, based upon identification of causal pathways, with a focus on biologics. A systematic search of the literature was made using Medline, and publications were selected on the basis of their relevance to the topic. Despite strong preclinical data for many of the more recently identified asthma targets, especially those relating to the T-helper 2 allergic pathway, clinical trials with specific biologics in moderate to severe asthma as a group have been disappointing. However, subgroup analyses based upon pathway-specific biomarkers suggest specific endotypes that are responsive. Application of hypothesis-free analytical approaches (the 'omics') to well-defined phenotypes is leading to the stratification of asthma along causal pathways. Refinement of this approach is likely to be the future for diagnosing and treating this group of diseases, as well as helping to define new causal pathways. The identification of responders and nonresponders to targeted asthma treatments provides a new way of looking at asthma diagnosis and management, especially with biologics that are costly. The identification of novel biomarkers linked to well-phenotyped patients provides a stratified approach to disease management beyond simple disease severity and involving causal pathways. In order to achieve this effectively, a closer interaction will be required between industry (therapeutic and diagnostic), academia and health workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.